2020
DOI: 10.5582/ddt.2020.03012
|View full text |Cite
|
Sign up to set email alerts
|

Effects of the combined administration of risedronate and menatetrenone on bone loss induced by tacrolimus in rats

Abstract: Bisphosphonate, menatetrenone, combined administration, bone loss, tacrolimus Tacrolimus, a calcineurin inhibitor, affects bone metabolism and increases the risk of fracture due to marked bone loss. Bisphosphonates increase the bone mineral density (BMD) in osteoporosis patients. Menatetrenone has less positive effects on BMD but reduces the risk of fracture by improving bone quality. In this study, we investigated the effectiveness of the combined administration of risedronate and menatetrenone against bone l… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Publication Types

Select...

Relationship

0
0

Authors

Journals

citations
Cited by 0 publications
references
References 39 publications
0
0
0
Order By: Relevance

No citations

Set email alert for when this publication receives citations?